It is worth noting that almost all patients with strong HER2 scores (IHC 3+) also received trastuzumab, although that number was lower in the control arm (93.5% vs. 84.0%), potentially ...

(2) The study only tested one trastuzumab-resistant and one trastuzumab-sensitive cell line. It is unclear whether these findings are applicable to other HER2-positive tumor cell lines, such as ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

The membrane-associated glycoprotein mucin-4 (MUC4) could block inhibitory actions of trastuzumab by directly binding with HER2, preventing interaction between the drug and its molecular target.

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy. The Food and Drug ...

Since 2022, Enhertu has been approved in the U.S. to treat advanced breast tumors expressing “low,” but still detectable, levels of the HER2 protein. With its new decision, the agency widened ...

HER2-overexpressing breast cancer Trastuzumab, in combination with an anthracycline- and taxane-containing chemotherapy regimen, has become the universally-accepted standard of care for high-risk ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results. The FDA has granted ...